Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.30

Mkt cap

14M

Volume

128K

High

1.33

P/E Ratio

-0.49

52-wk high

7.33

Low

1.28

Div yield

N/A

52-wk low

1.10

NRX Pharmaceuticals (NASDAQ:NRXP) reported a Q3 EPS loss of $(0.07), surpassing the consensus estimate of $(0.12) by 41.67%. The reported loss shows a 50% improvement from the $(0.14) per share loss in the same quarter of the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:01 am

NRX Pharmaceuticals (NASDAQ:NRXP) is scheduled to release its quarterly earnings report on November 14, 2023. Analysts predict an EPS of $-0.12. Investors will be looking for an earnings beat and positive guidance for future growth. Historically, NRXP's stock price has reacted to past earnings performances, with a mix of positive and negative changes post-announcement. The stock is currently trading at $0.3299, down 64.57% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 4:02 pm

NRx Pharmaceuticals and Nephron Pharmaceuticals have signed an agreement to manufacture a version of Ketamine for treating suicidal depression. The partners aim to submit a New Drug Application by March 1, 2024, and target a finished drug with two-year shelf stability for November 2024, pending FDA approval.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:55 am

NRx Pharmaceuticals has signed a contract to develop a version of Ketamine suitable for intravenous administration under current FDA manufacturing regulations. Existing supplies of Ketamine are not labeled for treatment of depression and suicidality and often do not meet modern manufacturing requirements for single-dose injectable medications.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:23 am

NRx Pharmaceuticals has announced a strategic acceleration of its plans to develop a commercial form of NRX-100 (Intravenous Ketamine) to treat acute depression and suicidality.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 10:50 am

Delta Apparel shares rose by 8.1% in pre-market trading after the company received an unsolicited offer to purchase its Salt Life business. Other notable pre-market movers include VIQ Solutions, Molekule Group, AgileThought, ALX Oncology Holdings, SIGNA Sports United, Loop Media, Renalytix, MSP Recovery, and SeaStar Medical Holding. On the losing side, AERWINS Technologies, SmileDirectClub, Nisun International Enterprise Development Group, Actelis Networks, NRx Pharmaceuticals, Eastside Distilling, OpGen, Better Choice Company, IceCure Medical, and Femasys saw declines.

Portfolio Pulse from Lisa Levin

October 03, 2023 | 12:02 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has received FDA clearance to proceed with human trials for its Investigational New Drug (IND) application for NRX-101, aimed at treating Chronic Pain. The IND application is based on pioneering research on the use of D-cycloserine, a key ingredient of NRX-101, and a recently licensed US Patent for the use of D-cycloserine in pain treatment.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:49 am

NRX Pharmaceuticals has published a shareholder update letter, indicating a potential marketing application submission to the FDA for NRX-100, which is expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:50 am

NRX Pharmaceuticals has signed a data sharing agreement that demonstrates the efficacy and safety of intravenous ketamine for treating suicidal bipolar depression. The company plans to present this data to the FDA with the aim of identifying a path to a New Drug Application (NDA).

Portfolio Pulse from Benzinga Newsdesk

September 15, 2023 | 10:55 am

NRx Pharmaceuticals has entered into an agreement with LifeSci Associates to provide financial services and support. This has led to an increase in NRx Pharmaceuticals' share prices.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 8:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.